GlassScriptPhysician profile
Kristin Garner Freeman
NPI 1316382906
$1,804.57
in general payments reported to CMS, 2019-2025
24 companies · $96.62 in 2025
The $96.62 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $60.53 · 2022: $448 · 2023: $914 · 2024: $286 · 2025: $96.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,296.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $341.52 | 2021-2024 | |
| Lilly USA, LLC | $314.96 | 2022-2024 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.81 | 2022-2024 | Jardiance |
| Novo Nordisk INC | $128.10 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $107.76 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $77.59 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $68.40 | 2022-2023 | Rexulti |
| Pfizer INC. | $63.41 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $60.98 | 2023-2024 | |
| Cleerly, INC. | $51.41 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Bayer Healthcare Pharmaceuticals INC. | $48.56 | 2023 | |
| Amgen INC. | $45.37 | 2023-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $43.68 | 2022-2023 | Freestyle Libre |
| Mannkind Corporation | $42.91 | 2023 | Afrezza |
| Dexcom, INC. | $30.63 | 2022-2024 | Dexcom G6 Transmitter |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $26.60 | 2025 | |
| Hikma Pharmaceuticals USA | $23.42 | 2022 | |
| Medtronic, INC. | $19.04 | 2022 | |
| Halozyme INC | $17.08 | 2023 | |
| Amarin Pharma, INC. | $15.29 | 2022 | |
| Horizon Therapeutics Plc | $14.91 | 2022 | |
| Antares Pharma, INC. | $13.63 | 2024 | Xyosted |
| Ibsa Pharma INC. | $12.90 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristin Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.